Explore /
Poster
/ Nivolumab and brentuximab vedotin (BV)-based, response‐adapted treatment in children, adolescents, and young adults (CAYA) with standard-risk relapsed/refractory classical Hodgkin lymphoma (R/R cHL): Primary analysis.

Nivolumab and brentuximab vedotin (BV)-based, response‐adapted treatment in children, adolescents, and young adults (CAYA) with standard-risk relapsed/refractory classical Hodgkin lymphoma (R/R cHL): Primary analysis.

Authors

Peter D. Cole

Rutger’s Cancer Institute of New Jersey, New Brunswick, NJ

Peter D. Cole , Christine Mauz-Körholz , Maurizio Mascarin , Gérard Michel , Stacy Cooper , Auke Beishuizen , Kasey J. Leger , Loredana Amoroso , Salvatore Buffardi , Charlotte Rigaud , Markus Puhlmann , Stephen Francis , Mariana Sacchi , Richard A. Drachtman , Paul David Harker-Murray , Thierry Leblanc , Stephen Daw , Kara M. Kelly

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Discussion Session

Session Title

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Track

Hematologic Malignancies

Sub Track

Hodgkin Lymphoma

Clinical Trial Registration Number

NCT02927769

Citation

J Clin Oncol 38: 2020 (suppl; abstr 8013)

DOI

10.1200/JCO.2020.38.15_suppl.8013

Abstract #

8013

Poster Bd #

346

Abstract Disclosures

Similar Posters

Poster

2023 ASCO Annual Meeting

$Response-adapted therapy (tx) with nivolumab plus brentuximab vedotin (nivo + BV) without autologous hematopoietic cell transplantation (auto-HCT) in children, adolescents, and young adults (CAYA) with low-risk relapsed/refractory (R/R) classic Hodgkin lymphoma (cHL): CheckMate 744.$